文献速递造血干细胞移植与细胞治疗

活化蛋白C经PAR1偏向性信号通路改善慢性移植物抗宿主病

Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells.
PubMed 文献 · Blood · 2019-06-26

在已建立慢性GVHD的小鼠中,野生型活化蛋白C(APC)使闭塞性细支气管炎所致的肺功能障碍恢复正常;保留细胞保护功能但抗凝活性大幅降低的信号选择性APC变体(3A-APC、5A-APC)效果相似。机制涉及供者T细胞PAR1在Arg46的非经典切割,APC抗凝活性并非必需,而抗炎与细胞保护信号至关重要。

要点

  • 野生型APC可逆转小鼠cGVHD的闭塞性细支气管炎性肺功能障碍。
  • 3A-APC或5A-APC抗凝活性大幅降低但细胞保护功能正常,效果与野生型APC相似。
  • 供者T细胞PAR1 Arg46切割(非经典)介导保护,Gln46-PAR1突变供者无此效应。

核心结论

  • APC的抗凝活性对改善cGVHD并非必需,而抗炎信号与细胞保护性细胞信号是必需的。
  • 供者T细胞APC诱导的PAR1 Arg46非经典切割与cGVHD减轻相关。
  • 3A-APC在缺血性卒中2期临床试验未提出安全性问题,为临床cGVHD治疗测试提供基础平台。

研究设计与样本

  • 在已建立慢性GVHD的小鼠中给予重组鼠野生型APC或信号选择性APC变体(3A-APC、5A-APC)。
  • 使用WT PAR1、Gln41-PAR1突变或Gln46-PAR1突变供者T细胞受体小鼠评估cGVHD。

主要发现

  • 野生型APC使闭塞性细支气管炎诱导的肺功能障碍恢复正常。
  • 3A-APC或5A-APC抗凝活性大幅降低但细胞保护特性正常,提供与野生型APC相似的结果。
  • 野生型APC及信号选择性变体减少滤泡辅助性T细胞、生发中心形成、免疫球蛋白和胶原沉积。
  • 接受WT PAR1或Gln41-PAR1突变供者T细胞的小鼠cGVHD减轻,而接受Gln46-PAR1突变供者T细胞的小鼠未减轻。

关键数值与推荐

  • 3A-APC为赖氨酸191-193替换为3个丙氨酸的APC;5A-APC为赖氨酸191-193替换为3个丙氨酸且精氨酸229/230替换为2个丙氨酸。
  • 野生型APC可在Arg41或Arg46切割蛋白酶激活受体1(PAR1),后者引起抗炎信号。

临床怎么用

  • 原文指出APC抗凝活性非必需而抗炎与细胞保护信号必需,为临床cGVHD治疗测试提供基础平台。
  • 3A-APC在缺血性卒中2期临床试验未提出安全性问题。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Soluble thrombomodulin plasma concentrations are elevated in steroid-resistant graft-versus-host disease (GVHD), implying endothelial hypofunctioning for thrombomodulin-dependent generation of activated protein C's (APC) anticoagulant, anti-inflammatory, and antiapoptotic functions. Recombinant thrombomodulin or APC administration decreases acute GVHD, manifested by intense inflammation and tissue destruction. Here, we administered recombinant murine wild-type (WT) APC to mice with established chronic GVHD (cGVHD), a less-inflammatory autoimmune-like disease. WT APC normalized bronchiolitis obliterans-induced pulmonary dysfunction. Signaling-selective APC variants (3A-APC [APC with lysine 191-193 replaced with 3 alanines] or 5A-APC [APC with lysine 191-193 replaced with 3 alanines and arginine 229/230 replaced with 2 alanines]) with normal cytoprotective properties, but greatly reduced anticoagulant activity, provided similar results. Mechanistically, WT APC and signaling-selective variants reduced T follicular helper cells, germinal center formation, immunoglobulin, and collagen deposition. WT APC can potentially cleave protease-activated receptor 1 (PAR1) at Arg41 or Arg46, the latter causing anti-inflammatory signaling. cGVHD was reduced in recipients of T cells from WT PAR1 or mutated Gln41-PAR1 donors but not from mutated Gln46-PAR1 donors. These data implicate donor T-cell APC-induced noncanonical cleavage at Arg46-PAR1, which is known to confer cytoprotective and anti-inflammatory activities. Together, these data indicate that APC anticoagulant activity is dispensable, whereas anti-inflammatory signaling and cytoprotective cell signaling by APC are essential. Because a phase 2 ischemic stroke clinical trial did not raise any safety issues for 3A-APC treatment, our studies provide a foundational platform for testing in clinical cGVHD therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sinha RK, Flynn R, Zaiken M, et al. Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. Blood. 2019. PMID: 31243040. doi:10.1182/blood.2019001259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。